Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review

References

• MorranCSmithDCAndersonDAMcArdleCSIncidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemeticsBr Med J1979113231324445053
   PubMed Web of Science ®Google Scholar
• CoatesADillenbeckCFMcNeilDROn the receiving end – II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapyEur J Cancer Clin Oncol198319163316376315445
   PubMedGoogle Scholar
• GriffinAMButowPNCoatesASOn the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993Ann Oncol199671891958777177
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMGrallaRJAprepitant Protocol 052 Study GroupThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study GroupJ Clin Oncol2003214112411914559886
   PubMed Web of Science ®Google Scholar
• Poli-BigelliSRodrigues-PereiraJCaridesADAprepitant Protocol 054 Study GroupAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin AmericaCancer2003973090309812784346
   PubMed Web of Science ®Google Scholar
• NaeimADySMLorenzKASanatiHWallingAAschSMEvidence-based recommendations for cancer nausea and vomitingJ Clin Oncol2008263903391018688059
   PubMed Web of Science ®Google Scholar
• HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med20083582482249418525044
   PubMed Web of Science ®Google Scholar
• American Society of Health-System PharmacistTherapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgeryAm J Health Syst Pharm199856729764
   Web of Science ®Google Scholar
• KrisMGCubedduLXGrallaRJAre more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatinCancer199678219321988918414
   PubMed Web of Science ®Google Scholar
• TavorathRHeskethPJDrug treatment of chemotherapy-induced delayed emesisDrugs1996526396489118814
   PubMed Web of Science ®Google Scholar
• WangSCBorisonHLThe vomiting center: a critical experimental analysisArch Neurol Psychiatry195063928941
   PubMedGoogle Scholar
• HornbyPJCentral neurocircuitry associated with emesisAm J Med2001111Suppl 8A106S112S11749934
   PubMed Web of Science ®Google Scholar
• MillerADGrelotSNeural control of respiratory muscle activation during vomitingMillerADBianchiALBishopBPNeural Control of the Respiratory MusclesBoca Raton, FLCRC Press1997239248
   Google Scholar
• MillerADLeslieRAThe area postrema and vomitingFront Neuroendocrinol1994153013207895890
   PubMed Web of Science ®Google Scholar
• BorisonHLArea postrema: chemoreceptor circumventricular organ of the medulla oblongataProg Neurobiol1989323513902660187
   PubMed Web of Science ®Google Scholar
• HigginsGAKilpatrickGJBunceKTJonesBJTyersMB5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferretBr J Pharmacol1989972472552720310
   PubMed Web of Science ®Google Scholar
• CarpenterDOBriggsDBStromingerNResponses of neurons of canine area postrema to neurotransmitters and peptidesCell Mol Neurobiol198331131266140078
   PubMed Web of Science ®Google Scholar
• CarpenterDOBriggsDBStromingerNPeptide-induced emesis in dogsBehav Brain Res1984112772816721920
   PubMed Web of Science ®Google Scholar
• AndrewsPLDavisCJBinghamSDavidsonHIHawthornJMaskellLThe abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticityCan J Physiol Pharmacol1990683253452178756
   PubMed Web of Science ®Google Scholar
• AndrewsPLSangerGJAbdominal vagal afferent neurons: an important target for the treatment of gastrointestinal dysfunctionCurr Opin Pharmacol2002265065612482726
   PubMed Web of Science ®Google Scholar
• NavariRMEinhornLHPassikSDA phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group studySupport Care Cancer20051352953415700131
   PubMed Web of Science ®Google Scholar
• NavariRMEinhornLHLoehrerPJSrA phase II trial of olanzapine, dexamethasone, and palonosetron for prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group studySupport Care Cancer2007151285129117375339
   PubMed Web of Science ®Google Scholar
• BowcockSJStockdaleADBoltonJAKangAARetsasSAntiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapyBr Med J (Clin Res Ed)198428818791879
   PubMed Web of Science ®Google Scholar
• LaszloJClarkRAHansonDCTysonLCrumplerLGrallaRLorazepam in cancer patients treated with cisplatin: a drug having anti-emetic, amnesic, and anxiolytic effectsJ Clin Oncol198538648694040158
   PubMed Web of Science ®Google Scholar
• BlowerPRThe role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesisEur J Cancer199026Suppl 1S8S112169786
   PubMed Web of Science ®Google Scholar
• TramèrMRCarrollDCampbellFAReynoldsDJMooreRAMcQuayHJCannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic reviewBMJ2001323162111440936
   PubMed Web of Science ®Google Scholar
• HeskethPJHarveyWHHarkerWGA randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesisJ Clin Oncol1994125966008120559
   PubMed Web of Science ®Google Scholar
• The Italian Group for Antiemetic ResearchDexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancerN Engl J Med1995332157990859
   PubMed Web of Science ®Google Scholar
• LatreilleJStewartDLabergeFDexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapySupport Care Cancer199533073128520877
   PubMed Web of Science ®Google Scholar
• IoannidisJPHeskethPJLauJContribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidenceJ Clin Oncol2000183409342211013282
   PubMed Web of Science ®Google Scholar
• Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Practice guideline report no. 12–13TorontoCancer Care Ontario2003
   Google Scholar
• del GiglioASoaresHPCaparrozCCastroPCGranisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trialsCancer2000893012308
   Web of Science ®Google Scholar
• JordanKHinkeAGrotheyASchmollHJGranisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysisSupport Care Cancer200513263115668744
   PubMed Web of Science ®Google Scholar
• KrisMGHeskethPJSomerfieldMRAmerican Society of Clinical Oncology guideline for antiemetics in oncology: update 2006J Clin Oncol2006242932294716717289
   PubMed Web of Science ®Google Scholar
• GelingOEichlerHGShould 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implicationsJ Clin Oncol2005231289129415718327
   PubMed Web of Science ®Google Scholar
• ToniniGVincenziBSantiniDNew drugs for chemotherapy-induced nausea and vomiting: focus on palonosetronExpert Opin Drug Metab Toxicol2005114314916922656
   PubMedGoogle Scholar
• GrallaRLichinitserMVan Der VegtSPalonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronAnn Oncol2003141570157714504060
   PubMed Web of Science ®Google Scholar
• EisenbergPFigueroa-VadilloJZamoraRImproved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetronCancer2003982473248214635083
   PubMed Web of Science ®Google Scholar
• AaproMSGrunbergSMManikhasGMA phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnn Oncol2006171441144916766588
   PubMed Web of Science ®Google Scholar
• AaproMSPalonosetron as an anti-emetic and anti-nausea agent in oncologyTher Clin Risk Manag200731009102018516316
   PubMedGoogle Scholar
• MassaEAstaraGMadedduCPalonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient responseCrit Rev Oncol Hematol2009701839118723369
   PubMed Web of Science ®Google Scholar
• SaitoMAogiKSekineIPalonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trialLancet Oncol200910211512419135415
   PubMed Web of Science ®Google Scholar
• HerrstedtJChemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxisAnn Oncol200718Suppl 2ii83ii8517491061
   PubMed Web of Science ®Google Scholar
• SchmollHJAaproMSPoli-BigelliSComparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatmentAnn Oncol2006171000100616524979
   PubMed Web of Science ®Google Scholar
• WarrDGHeskethPJGrallaRJEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyJ Clin Oncol2005232822283015837996
   PubMed Web of Science ®Google Scholar
• de WitRHerrstedtJRapoportBThe oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trialsEur J Cancer20044040341014746859
   PubMed Web of Science ®Google Scholar
• HerrstedtJMussHBWarrDGEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyCancer20051041548155516104039
   PubMed Web of Science ®Google Scholar
• GroteTHajdenbergJCartmellACombination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitantJ Support Oncol2006440340817004515
   PubMedGoogle Scholar
• RoilaFHeskethPJHerrstedtJPrevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus ConferenceAnn Oncol200617202816314401
   PubMed Web of Science ®Google Scholar
• Clinical Study Report 392MD/4/C Strakan Pharmacuetical Ltd62003
   Google Scholar
• Clinical Study Report 392MD/11/C Strakan Pharmacuetical Ltd62005
   Google Scholar
• HowellJSmeetsJDrenthHJGillDPharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomitingJ Oncol Pharm Pract2009320 [Epub ahead of print].
   Google Scholar
• Clinical Study Report 392MD/26/C Strakan Pharmacuetical Ltd62007
   Google Scholar
• AntonopoulosMSCaspiAGranisetron Transdermal Delivery, Product ProfilerP T20083310127
   Google Scholar
• ClarkeSEAustinNEBloomerJCMetabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosingXenobiotica199424111911317701853
   PubMed Web of Science ®Google Scholar
• A granisetron patchThe Medical Letter2008501301/13032103104
   Google Scholar
• Clinical Study Report 392MD/8/C Strakan Pharmacuetical Ltd52007
   Google Scholar
• Clinical Study Report 392MD/15/C Strakan Pharmacuetical Ltd72006
   Google Scholar
• CubedduLXPendergrassKRyanTEfficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study GroupAm J Clin Oncol1994171371468141105
   PubMed Web of Science ®Google Scholar
• JantunenITKatajaVVMuhonenTTAn overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomitingEur J Cancer19973366749071902
   PubMed Web of Science ®Google Scholar
• YonemuraMKatsumataNHashimotoHRandomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trialJpn J Clin Oncol20093944344819395466
   PubMed Web of Science ®Google Scholar
• JordanKGrotheyAKegelTFibichCSchöbertCAntiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomitingOnkologie200528889215662112
   PubMedGoogle Scholar
• TanMXuRSethRGranisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot studyCurr Med Res Opin20042087988215200746
   PubMed Web of Science ®Google Scholar
• AaproMSThuerlimannBSessaCDe PreeCBernhardJMaibachRSwiss Group for Clinical Cancer ResearchA randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesisAnn Oncol200314229129712562658
   PubMed Web of Science ®Google Scholar
• GebbiaVCannataGTestaAOndansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trialCancer19947419451528082100
   PubMed Web of Science ®Google Scholar
• AddelmanMErlichmanCFineSWarrDMurrayCPhase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomitingJ Clin Oncol199083373412153767
   PubMed Web of Science ®Google Scholar
• del GiglioASoaresHPCaparrozCCastroPCGranisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trialsCancer2000892301230811147601
   PubMed Web of Science ®Google Scholar
• NavariRMReinhardtRRGrallaRJReduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist: L-754,030 Antiemetic Trials GroupN Engl J Med19993401901959917226
   PubMed Web of Science ®Google Scholar
• SchmollHJAaproMSPoli-BigelliSComparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatmentAnn Oncol2006171000100616524979
   PubMed Web of Science ®Google Scholar
• WarrDGGrunbergSMGrallaRJThe oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trialsEur J Cancer2005411278128515939263
   PubMed Web of Science ®Google Scholar
• AbdelsayedGGManagement of radiation-induced nausea and vomitingExp Hematol2007354 Suppl 1343617379085
   PubMed Web of Science ®Google Scholar
• TucaARocaRSalaCEfficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trialJ Pain Symptom Manage20093725927018789638
   PubMed Web of Science ®Google Scholar
• HerrstedtJDomberdonwskyAnti-emetic threapy in cancer chemotherapy: current statusBasic Clin Pharmacol Toxicol2007100114315017697032
   PubMed Web of Science ®Google Scholar
• RipamontiCMercadanteSHow to use octreotide for malignant bowel obstructionJ Support Oncol20042435736415357519
   PubMedGoogle Scholar
• MercadanteSCasuccioAMangioneSMedical treatment for inoperable malignant bowel obstruction: a qualitative systematic reviewJ Pain Symptom Manage200733221722317280927
   PubMed Web of Science ®Google Scholar